These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Therapeutic targeting of splicing in cancer. Lee SC; Abdel-Wahab O Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132 [TBL] [Abstract][Full Text] [Related]
29. The role of alternative splicing in cancer: From oncogenesis to drug resistance. Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093 [TBL] [Abstract][Full Text] [Related]
30. The role of microRNAs in normal and malignant hematopoiesis. Vasilatou D; Papageorgiou S; Pappa V; Papageorgiou E; Dervenoulas J Eur J Haematol; 2010 Jan; 84(1):1-16. PubMed ID: 19744129 [TBL] [Abstract][Full Text] [Related]
34. Epigenetics of hematopoiesis and hematological malignancies. Hu D; Shilatifard A Genes Dev; 2016 Sep; 30(18):2021-2041. PubMed ID: 27798847 [TBL] [Abstract][Full Text] [Related]
35. Relative levels of alternative transcripts of the ING1 gene and lack of mutations of p33/ING1 in haematological malignancies. Bromidge T; Lynas C Leuk Res; 2002 Jul; 26(7):631-5. PubMed ID: 12008079 [TBL] [Abstract][Full Text] [Related]
36. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480 [TBL] [Abstract][Full Text] [Related]
37. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771 [No Abstract] [Full Text] [Related]